Does increased 11 β HSD‐ 1 activity induce adverse metabolic phenotype only in lean ?

Abstract

We read with interest article by Crowley et al (1). The authors a found an apparent decrease in 11 β HSD‐ 1 expression in subcutaneous adipose tissue (SAT) of deteriorators as compared to improvers. They explained it as compensatory decrease of 11 β HSD‐ 1 activity as consequence of overall adverse metabolic phenotype. It remained speculative whether visceral adipose tissue (VAT) 11 β HSD1 was increased in deteriorators. While this is consistent with recently published study by us (2), in which we found liver/portal circulation 11 β HSD1 activity to be increased in diabetics as compared to controls. However increased 11 β HSD1 activity was not seen in those who had BMI >23 m/kg2 (2). In this regard it will be interesting to know what was 11 β HSD1 expression in subgroup of those with Body Mass Index (BMI) >23 m/kg2 or >25 m/kg2 or >30 m/kg2. It is possible the difference between improvers and deteriorators was lost at higher BMI when other causative factors for diabetes (e.g. insulin resistance) exert more influence.

This article is protected by copyright. All rights reserved.

http://bit.ly/2TRHOJD